← Leaderboards
Michael Wang
University Of Tx Md Anderson Can Ctr
$3,493,311
Attributed
$7,351,745
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,351,745 · 5
By mechanism
R01$6,169,602 · 2
R21$1,182,143 · 3
Top collaborators
- Jin Wang8 shared
- Jennifer A. Woyach8 shared
- Samir Parekh5 shared
- Changying Jiang2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kapil N. Bhalla$16,921,043
- Srdan Verstovsek$1,168,238
- Changying Jiang$208,272
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistancePathway InteractionsRelapseMantle Cell LymphomaMouse ModelIn VitroIn VivoCell LineLymphoma CellNew Therapeutic TargetDrug ResistanceRefractoryAgammaglobulinaemia Tyrosine KinaseBaseEfficacy TestingTyrosine Kinase InhibitorB-LymphocytesMutantMutationPhase Ii Clinical TrialsResistance MechanismB Lymphoid MalignancyCellsClinic
Grant awards (19)
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$610,105
R01 · FY2024 · CA
Targeting SOX11 in Mantle Cell Lymphoma$534,024
R01 · FY2024 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$68,584
R01 · FY2024 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2023 · CA
Targeting SOX11 in Mantle Cell Lymphoma$550,887
R01 · FY2023 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$70,750
R01 · FY2023 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2022 · CA
Targeting SOX11 in Mantle Cell Lymphoma$550,887
R01 · FY2022 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$72,195
R01 · FY2022 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$641,550
R01 · FY2021 · CA
Targeting SOX11 in Mantle Cell Lymphoma$562,130
R01 · FY2021 · CA
Targeting the Unique Paracaspase MALT1 to Overcome Ibrutinib Resistance in Relapsed/Refractory MCL Patients$189,338
R21 · FY2021 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$671,549
R01 · FY2020 · CA
Targeting SOX11 in Mantle Cell Lymphoma$579,503
R01 · FY2020 · CA
Targeting the Unique Paracaspase MALT1 to Overcome Ibrutinib Resistance in Relapsed/Refractory MCL Patients$227,205
R21 · FY2020 · CA · contact PI
FoxM1 as a Novel Therapeutic Target to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma$174,000
R21 · FY2020 · CA · contact PI
FoxM1 as a Novel Therapeutic Target to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma$208,800
R21 · FY2019 · CA · contact PI
Overcoming Primary Ibrutinib Resistance in Mantle Cell Lymphoma Using Patient-Derived Models and Molecular Profiling$174,000
R21 · FY2017 · CA · contact PI
Overcoming Primary Ibrutinib Resistance in Mantle Cell Lymphoma Using Patient-Derived Models and Molecular Profiling$208,800
R21 · FY2016 · CA · contact PI